Swiss drugmaker Roche Holding AG announced Monday a $43.7 billion offer for the outstanding shares in biotech company Genentech Inc., to assist its hunt for new medicines.

Roche, based in Basel, Switzerland, plans to offer $89 per share for the 44 percent of Genentech that it doesn’t already own — or 8.8 percent more than the Friday closing price.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]